Harmony Biosciences Holdings (HRMY) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $29.05
• Market Cap: $1.62B
• P/E Ratio: 8.89
• EPS: $3.17
• 52-Week High: $40.87
• 52-Week Low: $25.52

Market Sentiment

Harmony Biosciences Holdings currently has a Neutral sentiment score of -0.13.

About Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc. is a prominent commercial-stage pharmaceutical company headquartered in Plymouth Meeting, Pennsylvania, focusing on the development and commercialization of innovative therapies for rare neurological disorders. The company’s flagship products target conditions such as narcolepsy, reflecting its commitment to addressing significant unmet medical needs in the neurology field. With a robust pipeline supported by advanced research capabilities, Harmony is dedica...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Harmony Biosciences Holdings and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does HRMY pay dividends?

Harmony Biosciences Holdings (HRMY) does not currently pay a regular dividend.

What is HRMY's P/E ratio?

Harmony Biosciences Holdings has a price-to-earnings (P/E) ratio of 8.89.

What is HRMY's market cap?

Harmony Biosciences Holdings (HRMY) has a market capitalization of $1.62B with a current stock price of $29.05.